Description: Immunosuppression following kidney transplantation leads to an increase in BK virus activity, causing kidney damage and loss. A novel RNA-targeting therapy has been developed that homes to the kidney, and inhibits BK virus activity. Among others, in this project a novel in vivo BK virus-inhibiting model has been developed to screen and optimize antisense oligonucleotide candidates. The LUMC spin-out company Hybridize Pharma has been founded in 2019 to advance the development of this highly promising therapy.
Learn more about Hybridize Therapeutics and its new therapy against kidney loss due to BK-virus infection.
